Crispr Therapeutics AG (NASDAQ:CRSP) insider Tyler Dylan-Hyde sold 66,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $28.03, for a total transaction of $1,849,980.00. Following the sale, the insider now directly owns 25,204 shares in the company, valued at approximately $706,468.12. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Tyler Dylan-Hyde also recently made the following trade(s):

  • On Tuesday, January 2nd, Tyler Dylan-Hyde sold 38,000 shares of Crispr Therapeutics stock. The stock was sold at an average price of $21.64, for a total transaction of $822,320.00.
  • On Thursday, December 28th, Tyler Dylan-Hyde sold 700 shares of Crispr Therapeutics stock. The shares were sold at an average price of $21.75, for a total transaction of $15,225.00.
  • On Friday, December 29th, Tyler Dylan-Hyde sold 31,000 shares of Crispr Therapeutics stock. The shares were sold at an average price of $22.72, for a total transaction of $704,320.00.
  • On Friday, December 22nd, Tyler Dylan-Hyde sold 15,000 shares of Crispr Therapeutics stock. The shares were sold at an average price of $20.55, for a total value of $308,250.00.
  • On Friday, December 15th, Tyler Dylan-Hyde sold 15,000 shares of Crispr Therapeutics stock. The shares were sold at an average price of $18.90, for a total value of $283,500.00.

Crispr Therapeutics AG (NASDAQ:CRSP) traded up $2.49 during midday trading on Monday, reaching $37.37. The company’s stock had a trading volume of 877,424 shares, compared to its average volume of 1,116,004. The firm has a market cap of $1,740.00 and a P/E ratio of -116.78. Crispr Therapeutics AG has a 52 week low of $11.63 and a 52 week high of $45.00.

CRSP has been the topic of a number of research reports. BidaskClub upgraded Crispr Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, January 25th. Zacks Investment Research lowered Crispr Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, January 25th. Cann reiterated a “hold” rating on shares of Crispr Therapeutics in a report on Sunday, December 10th. SunTrust Banks upgraded Crispr Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, January 23rd. Finally, Piper Jaffray Companies started coverage on shares of Crispr Therapeutics in a report on Friday, December 22nd. They issued an “overweight” rating on the stock. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. Crispr Therapeutics currently has an average rating of “Buy” and a consensus target price of $22.81.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CRSP. BlackRock Inc. grew its position in Crispr Therapeutics by 16,623.9% in the 4th quarter. BlackRock Inc. now owns 552,558 shares of the company’s stock valued at $12,974,000 after acquiring an additional 549,254 shares in the last quarter. Opaleye Management Inc. acquired a new position in Crispr Therapeutics in the 4th quarter valued at about $6,597,000. Capital Advisors Inc. OK acquired a new position in Crispr Therapeutics in the 4th quarter valued at about $3,515,000. Allianz Asset Management GmbH acquired a new position in Crispr Therapeutics in the 3rd quarter valued at about $2,384,000. Finally, Granahan Investment Management Inc. MA grew its position in Crispr Therapeutics by 51.7% in the 3rd quarter. Granahan Investment Management Inc. MA now owns 263,746 shares of the company’s stock valued at $4,713,000 after acquiring an additional 89,839 shares in the last quarter. 22.74% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “Insider Selling: Crispr Therapeutics AG (NASDAQ:CRSP) Insider Sells 66,000 Shares of Stock” was posted by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are accessing this report on another site, it was illegally stolen and reposted in violation of international trademark & copyright law. The legal version of this report can be read at https://www.truebluetribune.com/2018/02/13/crispr-therapeutics-ag-crsp-insider-sells-1849980-00-in-stock.html.

Crispr Therapeutics Company Profile

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.

Insider Buying and Selling by Quarter for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Crispr Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.